OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

HTML

Year: 2007
Type: article
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2006.07.2066
Authors: Joachim Drevs, Patrizia Siegert, Michael Medinger, Klaus Mross, Ralph Strecker, Ute Zirrgiebel, Jan Harder, Hubert Blum, Jane Robertson, Juliane M. Jürgensmeier, Thomas A. Puchalski, Helen Young, Owain Saunders, Clemens Unger
Institutions: University of Freiburg, University Medical Center Freiburg
Language: English

Topic: Angiogenesis and VEGF in Cancer
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: AZD2171, sunitinib, VEGFR inhibitors, oral anticancer drugs, advanced solid tumors, liver metastasis, maximum tolerated dose, dose-limiting toxicity, hypertension, pharmacokinetics, pharmacodynamics, dynamic contrast-enhanced MRI, soluble VEGF receptor-2, anticancer activity, safety and tolerability
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2137758263
FWCI: 12.47
Cites: 31
Cited by: 318
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms